Merck raises stakes in lung cancer as rivals close in

LOS ANGELES (Reuters) – Merck & Co Inc, maker of the only immunotherapy approved for patients newly-diagnosed with the most common type of lung cancer, could solidify its lead by playing the long game, even as rivals edge closer.


Source: Reuters Medical News

Leave a Reply

Your email address will not be published. Required fields are marked *